TAS-102 and Anlotinib in ≥3 Lines mGC
NCT05029102
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
45
Enrollment
OTHER
Sponsor class
Conditions
Gastric Cancer
Interventions
DRUG:
TAS 102
DRUG:
Anlotinib
Sponsor
Zhejiang University